
Jeroen C Jansen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4289336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer, 2000, 88, 2811-2816.	4.1	260
2	SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncology, The, 2010, 11, 366-372.	10.7	256
3	CD44 Expression Predicts Local Recurrence after Radiotherapy in Larynx Cancer. Clinical Cancer Research, 2010, 16, 5329-5338.	7.0	173
4	Jugular and vagal paragangliomas: Systematic study of management with surgery and radiotherapy. Head and Neck, 2013, 35, 1195-1204.	2.0	160
5	Nearly all hereditary paragangliomas in The Netherlands are caused by two founder mutations in the SDHDgene. Genes Chromosomes and Cancer, 2001, 31, 274-281.	2.8	149
6	SDHAF2 (PGL2-SDH5) and Hereditary Head and Neck Paraganglioma. Clinical Cancer Research, 2011, 17, 247-254.	7.0	137
7	Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. BMC Medical Genetics, 2006, 7, 1.	2.1	112
8	Increased Urinary Excretion of 3-Methoxytyramine in Patients with Head and Neck Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 209-214.	3.6	105
9	Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncology, 2013, 49, 15-19.	1.5	100
10	Systemic and local human papillomavirus 16â€specific Tâ€cell immunity in patients with head and neck cancer. International Journal of Cancer, 2012, 131, E74-85.	5.1	90
11	Validation of a Gene Expression Signature for Assessment of Lymph Node Metastasis in Oral Squamous Cell Carcinoma. Journal of Clinical Oncology, 2012, 30, 4104-4110.	1.6	75
12	Malignant Paragangliomas Associated with Mutations in the Succinate Dehydrogenase D Gene. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1245-1248.	3.6	72
13	Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1386-E1393.	3.6	68
14	The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features. Journal of Medical Genetics, 2004, 41, e99-e99.	3.2	63
15	Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 438-445.	3.6	62
16	Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer, 2000, 88, 2811-6.	4.1	58
17	Quality of Life in 807ÂPatients with Vestibular Schwannoma: Comparing Treatment Modalities. Otolaryngology - Head and Neck Surgery, 2017, 157, 92-98.	1.9	54
18	Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. BMC Medical Genetics, 2010, 11, 92.	2.1	52

2

JEROEN C JANSEN

#	Article	lF	CITATIONS
19	High prevalence of founder mutations of the succinate dehydrogenase genes in the Netherlands. Clinical Genetics, 2012, 81, 284-288.	2.0	51
20	The penetrance of paraganglioma and pheochromocytoma in <i><scp>SDHB</scp></i> germline mutation carriers. Clinical Genetics, 2018, 93, 60-66.	2.0	51
21	First experiences with genetic counselling based on predictive DNA diagnosis in hereditary glomus tumours (paragangliomas) Journal of Medical Genetics, 1996, 33, 379-383.	3.2	50
22	Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clinical Endocrinology, 2011, 75, 650-655.	2.4	49
23	Management of vagal paraganglioma: Is operative resection really the best option?. Surgery, 2005, 137, 225-228.	1.9	44
24	Regression and local control rates after radiotherapy for jugulotympanic paragangliomas: Systematic review and meta-analysis. Radiotherapy and Oncology, 2013, 106, 161-168.	0.6	41
25	Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. European Journal of Endocrinology, 2005, 152, 87-94.	3.7	39
26	Paraganglioma and pheochromocytoma upon maternal transmission of SDHDmutations. BMC Medical Genetics, 2014, 15, 111.	2.1	38
27	The phenotype of SDHB germline mutation carriers: a nationwide study. European Journal of Endocrinology, 2017, 177, 115-125.	3.7	38
28	High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. European Journal of Human Genetics, 2013, 21, 469-470.	2.8	37
29	Confinement of PGL, an Imprinted Gene Causing Hereditary Paragangliomas, to a 2-cM Interval on 11q22-q23 and Exclusion of DRD2 and NCAM as Candidate Genes. European Journal of Human Genetics, 1996, 4, 267-273.	2.8	36
30	The first Dutch SDHB founder deletion in paraganglioma – pheochromocytoma patients. BMC Medical Genetics, 2009, 10, 34.	2.1	35
31	Validating the Penn Acoustic Neuroma Quality of Life Scale in a Sample of Dutch Patients Recently Diagnosed With Vestibular Schwannoma. Otology and Neurotology, 2013, 34, 952-957.	1.3	31
32	Founder Effect at PGL1 in Hereditary Head and Neck Paraganglioma Families from The Netherlands. American Journal of Human Genetics, 1998, 63, 468-473.	6.2	30
33	The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. European Journal of Human Genetics, 2010, 18, 62-66.	2.8	30
34	Results from Craniocaudal Carotid Body Tumor Resection: Should It be the Standard Surgical Approach?. European Journal of Vascular and Endovascular Surgery, 2013, 46, 624-629.	1.5	30
35	Reduced quality of life in patients with head-and-neck paragangliomas. European Journal of Endocrinology, 2008, 158, 247-253.	3.7	26
36	Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas. Endocrine-Related Cancer, 2009, 16, 527-536.	3.1	23

JEROEN C JANSEN

#	Article	IF	CITATIONS
37	Effects of octreotide therapy in progressive head and neck paragangliomas: Case series. Head and Neck, 2013, 35, E391-6.	2.0	21
38	Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget, 2017, 8, 14525-14536.	1.8	21
39	Pheochromocytomas detected by biochemical screening in predisposed subjects are associated with lower prevalence of clinical and biochemical manifestations and smaller tumors than pheochromocytomas detected by signs and symptoms. European Journal of Endocrinology, 2010, 163, 121-127.	3.7	18
40	Normal Life Expectancy for Paraganglioma Patients: A 50-Year-Old Cohort Revisited. Skull Base, 2011, 21, 385-388.	0.4	18
41	Quality of life is decreased in patients with paragangliomas. European Journal of Endocrinology, 2013, 168, 689-697.	3.7	18
42	Age and Tumor Volume Predict Growth of Carotid and Vagal Body Paragangliomas. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, 497-505.	0.8	18
43	EGFR and αvβ6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region. Cancers, 2020, 12, 1474.	3.7	17
44	Emotional Intelligence in Association With Quality of Life in Patients Recently Diagnosed With Vestibular Schwannoma. Otology and Neurotology, 2014, 35, 1650-1657.	1.3	16
45	Increased Mortality in SDHB but Not in SDHD Pathogenic Variant Carriers. Cancers, 2019, 11, 103.	3.7	16
46	Variant type is associated with disease characteristics in SDHB, SDHC and SDHD-linked phaeochromocytoma–paraganglioma. Journal of Medical Genetics, 2020, 57, 96-103.	3.2	16
47	Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients. Endocrine-Related Cancer, 2009, 16, 929-937.	3.1	15
48	Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in <i>SDHD</i> -linked paragangliomas: <i>SLC22A18</i> and <i>CDKN1C</i> are candidate tumour modifiers. Human Molecular Genetics, 2016, 25, 3715-3728.	2.9	15
49	Evaluation of the modified Pittsburgh classification for predicting the diseaseâ€free survival outcome of squamous cell carcinoma of the external auditory canal. Head and Neck, 2020, 42, 3609-3622.	2.0	14
50	Fully Automated 3D Vestibular Schwannoma Segmentation with and without Gadolinium-based Contrast Material: A Multicenter, Multivendor Study. Radiology: Artificial Intelligence, 2022, 4, .	5.8	11
51	No evidence for increased mortality in SDHD variant carriers compared with the general population. European Journal of Human Genetics, 2015, 23, 1713-1716.	2.8	10
52	Recurrent Rhabdoid Meningioma: Case Report. Skull Base, 2003, 13, 51-54.	0.4	10
53	Two Immigrants with Tuberculosis of the Ear, Nose, and Throat Region with Skull Base and Cranial Nerve Involvement. Case Reports in Medicine, 2011, 2011, 1-5.	0.7	9
54	No difference in phenotype of the main <scp>D</scp> utch <i><scp>SDHD</scp></i> founder mutations. Clinical Endocrinology, 2013, 79, 824-831.	2.4	9

JEROEN C JANSEN

#	Article	IF	CITATIONS
55	Phenotype of SDHB mutation carriers in the Netherlands. Familial Cancer, 2014, 13, 651-657.	1.9	9
56	Nationwide study of patients with head and neck paragangliomas carrying <i>SDHB</i> germline mutations. BJS Open, 2018, 2, 62-69.	1.7	8
57	Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers. European Journal of Human Genetics, 2018, 26, 1339-1347.	2.8	8
58	Long-term voice outcomes of laryngeal framework surgery for unilateral vocal fold paralysis. European Archives of Oto-Rhino-Laryngology, 2022, 279, 1957-1965.	1.6	7
59	Carotid body tumors are not associated with an increased risk for sleep-disordered breathing. Sleep and Breathing, 2014, 18, 103-109.	1.7	6
60	Mathematical Models for Tumor Growth and the Reduction of Overtreatment. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, 072-078.	0.8	6
61	Germline <i>DLST</i> Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
62	Case of spontaneous regression of carotid body tumor in a SDHD mutant: a discussion on potential mechanisms based on a review of the literature. World Journal of Surgical Oncology, 2012, 10, 218.	1.9	4
63	Measurement of head and neck paragangliomas: is volumetric analysis worth the effort? A method comparison study. Clinical Otolaryngology, 2016, 41, 571-578.	1.2	4
64	Longâ€Term Quality of Life of Vestibular Schwannoma Patients: A Longitudinal Analysis. Otolaryngology - Head and Neck Surgery, 2023, 168, 210-217.	1.9	4
65	Management and outcome of middle ear adenomatous neuroendocrine tumours: A systematic review. Oral Oncology, 2021, 121, 105465.	1.5	3
66	SDHB variant type impacts phenotype and malignancy in pheochromocytoma-paraganglioma. Journal of Medical Genetics, 2021, , jmedgenet-2020-107656.	3.2	3
67	A prediction model for recurrence after translabyrinthine surgery for vestibular schwannoma: toward personalized postoperative surveillance. European Archives of Oto-Rhino-Laryngology, 2022, , 1.	1.6	3
68	Evaluation of subclasses for <scp>T4</scp> lassified squamous cell carcinoma of the external auditory canal. Head and Neck, 2022, , .	2.0	3
69	Head-and-neck paragangliomas are associated with sleep-related complaints, especially in the presence of carotid body tumors. Sleep and Breathing, 2012, 16, 527-534.	1.7	2
70	The impact of vestibular schwannoma and its management on employment. European Archives of Oto-Rhino-Laryngology, 2022, 279, 2819-2826.	1.6	2
71	A â€~Final Destination injury': Penetrating trauma of the neck and a pneumomediastinum by a metal part shot from a lawnmower. Trauma Case Reports, 2021, 31, 100379.	0.4	1
72	Multidimensional assessment of voice quality after injection augmentation of the vocal fold with autologous adipose tissue or calcium hydroxylapatite. European Archives of Oto-Rhino-Laryngology, 2021, , 1.	1.6	1

#	Article	IF	CITATIONS
73	Response to a letter to the editor "A prediction model for recurrence after translabyrinthine surgery for vestibular schwannoma: towards personalized postoperative surveillance― European Archives of Oto-Rhino-Laryngology, 2022, , 1.	1.6	1